Glenmark Pharma continues to maintain growth across all its crucial markets. Credit: T. Schneider/Shutterstock.com.

Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m).

Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

As per the deal, Glenmark Pharma is selling the stake in the life sciences unit for Rs615 for each share.

Following the divestiture, Glenmark Pharma will own a 7.84% stake in GLS. 

Glenmark Pharmaceuticals chairman and managing director Glenn Saldanha said: “We are pleased to announce this strategic transaction with Nirma, which marks a significant milestone in shaping an independent growth trajectory for GLS. 

“This deal aligns with our strategic intent of moving up the value chain to become an innovative/brand-led organisation, with continuous focus on our core therapeutic areas of dermatology, respiratory and oncology. 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“It also presents an opportunity for us to strengthen shareholder value through deleveraging and enhancing our overall return profile.” 

The conclusion of the deal is subject to necessary closing conditions and approvals from shareholders and regulators.

Following the deal closing, GLS will work as an independent API company under Nirma. 

Furthermore, Nirma will make a compulsory open offer to all GLS public shareholders.

Glenmark Pharma continues to maintain growth across all its crucial markets while focusing on return ratios, eventually generating value for the shareholders of the company. 

Kotak Investment Banking served as the exclusive financial adviser for Glenmark Pharma and GLS.

S&R Associates and Trilegal were the legal advisers to Glenmark Pharma and GLS, respectively.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact